Skip to main content
Clinical Trials/JPRN-jRCT1080222517
JPRN-jRCT1080222517UnknownUnknown

Actos Tablets specified drug-use survey <Survey on glycemic control in type 2 diabetic patients with a history of cerebral infarction>

TAKEDA PHARMACEUTICAL COMPANY LTD.0 sites500 target enrollmentStarted: June 10, 2014Last updated:

Trial Snapshot

Phase
Unknown
Sponsor
Enrollment
500

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
ot applicable to ot applicable (—)
Sex
All

Inclusion Criteria

  • Type 2 diabetic patients with a prior history of cerebral infarction who meet all the following conditions, [1] to [3], at the time of enrollment in the survey:
  • [1] First onset of cerebral infarction was at least 24 weeks prior to enrollment
  • [2] HbA1c values >= 6.5% within 12 weeks prior to the start of treatment with Actos Tablets
  • [3] No prior history of treatment with Actos Tablets since the first onset of cerebral infarction

Exclusion Criteria

  • Patients who meet any of the following conditions, [1] to [5], shall be excluded from the survey:
  • [1] Contraindication for Actos Tablets
  • [2] Prior history of recurrence of cerebral infarction
  • [3] Prior history of cerebral hemorrhage or subarachnoid hemorrhage
  • [4] Complications or prior history of myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease, atrial fibrillation, atrial flutter, or valvular disease
  • [5] Reduced cardiac function (defined as an ejection fraction [EF] <= 40%)

Investigators

Sponsor
TAKEDA PHARMACEUTICAL COMPANY LTD.

Similar Trials